SWISS drug manufacturer Novartis would experience a twofold blow if other countries following the same line of argument as India or if more markets started importing the Indian generic equivalent of patented drug Glivec, law and health experts said yesterday On Monday Novartis lost a seven-year battle to get a patent in India on its leukemia drug, Glivec. The drug, which is patented in more than 40 countries worldwide, costs R862.50 for each 400mg tablet in South Africa's private sector... Doctors Without Borders (MSF) said the ruling set a strong example for South Africa to follow as the Department of Trade and Industry was drafting amendments to the country's patent laws..."South Africans are missing out on affordable versions of life-saving medicines because generic competition is blocked by frivolous patents," said Julia Hill of MSF's access campaign...

Read article below.